Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with the latest twist in the Ozempic panic, polarizing data in genome editing, and another biotech in search of “strategic alternatives.”
